Scarica l'app Stockscreener
30.13
1.00%
-0.2609
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Viridian Therapeutics Inc Borsa (VRDN) Ultime notizie
Propel Bio Management LLC Makes New Investment in Viridian Therapeutics, Inc. $VRDN - MarketBeat
Viridian Therapeutics at TD Cowen Conference: Strategic Moves in TED Treatment By Investing.com - Investing.com South Africa
Viridian Therapeutics at TD Cowen Conference: Strategic Moves in TED Treatment - Investing.com Australia
[144] Viridian Therapeutics, Inc.DE SEC Filing - Stock Titan
Viridian Therapeutics Stock Up 75%, but One Fund Just Sold Off Its $69 Million Stake - AOL.com
Viridian Therapeutics, Inc. $VRDN Position Increased by Fisher Asset Management LLC - MarketBeat
Viridian Therapeutics, Inc. (VRDN): Investor Outlook on a Biotech Powerhouse with 38% Upside Potential - DirectorsTalk Interviews
Viridian Therapeutics (VRDN) Balances Rising Losses With Veligrotug Milestones and New Employee Stock Shelf Registration - Sahm
What analyst consensus says on Viridian Therapeutics Inc. stockRisk Management & Free Growth Oriented Trading Recommendations - mfd.ru
How (VRDN) Movements Inform Risk Allocation Models - Stock Traders Daily
Royal Bank Of Canada Has Lowered Expectations for Viridian Therapeutics (NASDAQ:VRDN) Stock Price - MarketBeat
Viridian Therapeutics (VRDN) Analyst Maintains Rating; Adjusts P - GuruFocus
RBC Adjusts Price Target on Viridian Therapeutics to $42 From $45, Maintains Outperform Rating - marketscreener.com
What Viridian Therapeutics (VRDN)'s 2025 Losses and Thyroid Eye Disease Milestones Mean For Shareholders - Yahoo Finance
VRDN Should I Buy - Intellectia AI
Decoding Viridian Therapeutics Inc (VRDN): A Strategic SWOT Insi - GuruFocus
Jefferies Maintains Buy, PT $45 for Viridian Therapeutics (VRDN) Feb 2026 - Meyka
VRDN Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Viridian Therapeutics (NASDAQ:VRDN) Releases Earnings Results, Misses Expectations By $0.18 EPS - MarketBeat
Jefferies raises Viridian Therapeutic stock price target on trial progress By Investing.com - Investing.com Canada
Viridian Therapeutics Inc reports results for the quarter ended September 30Earnings Summary - TradingView
Wedbush Cuts Viridian Therapeutics Price Target to $44 From $47, Maintains Outperform Rating - marketscreener.com
Evercore ISI reiterates Viridian Therapeutic stock rating on data conviction By Investing.com - Investing.com Canada
Viridian Therapeutics earnings beat by $0.64, revenue topped estimates - Investing.com
Viridian Therapeutics, Inc. (VRDN) Reports Q4 Loss, Misses Revenue Estimates - Yahoo Finance
Viridian Therapeutics earnings missed by $0.10, revenue fell short of estimates - Investing.com UK
Viridian Therapeutics Q4 revenue misses analyst expectations - TradingView
Viridian Therapeutics Reports Q4 and Full Year 2025 Financial Results - TradingView
TED drug veligrotug nears FDA decision as Viridian (NASDAQ: VRDN) ramps spend - Stock Titan
Viridian Therapeutics Highlights Recent Progress and Reports Fourth Quarter and Full Year 2025 Financial Results - Business Wire
Viridian Therapeutics (VRDN) TTM US$342.6 Million Loss Tests Bullish Growth Narratives - Sahm
Tech Rally: What is the implied volatility of Viridian Therapeutics IncTrade Exit Report & AI Optimized Trade Strategies - baoquankhu1.vn
Growth Review: Is Viridian Therapeutics Inc subject to activist investor interest2025 Price Momentum & Trade Opportunity Analysis - baoquankhu1.vn
VRDN PE Ratio & Valuation, Is VRDN Overvalued - Intellectia AI
Viridian Therapeutics Stock Up 75%, but One Fund Just Sold Off Its $69 Million Stake - The Motley Fool
Can Viridian Therapeutics Inc. stock double in the next year2025 Key Highlights & Real-Time Chart Breakout Alerts - mfd.ru
Can Viridian Therapeutics Inc. be the next market leader2025 Valuation Update & Long Hold Capital Preservation Plans - mfd.ru
Is Viridian Therapeutics Inc.’s ROIC above industry averageWeekly Risk Report & Free Community Supported Trade Ideas - mfd.ru
Viridian Preparing To Launch Its First Drug And A Fast Follower In TED - Citeline News & Insights
VRDN SEC FilingsViridian Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
What are Viridian Therapeutics Inc.’s earnings expectations2025 Valuation Update & Free Expert Approved Momentum Trade Ideas - mfd.ru
Viridian Therapeutics (VRDN) Projected to Post Quarterly Earnings on Thursday - MarketBeat
Viridian Therapeutics surveys impact of thyroid eye disease on daily life - Traders Union
Truist reiterates Viridian Therapeutic stock rating ahead of trial By Investing.com - Investing.com Canada
Viridian Therapeutics, Inc. (VRDN) Stock Analysis: A 50.75% Upside Potential In Biotech - DirectorsTalk Interviews
Viridian Therapeutics, Inc. (NASDAQ:VRDN) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Trading Systems Reacting to (VRDN) Volatility - Stock Traders Daily
Published on: 2026-02-13 20:43:42 - mfd.ru
What is the implied volatility of Viridian Therapeutics Inc.Weekly Investment Recap & Risk Managed Investment Strategies - mfd.ru
Viridian Therapeutics, Inc. (VRDN) Stock Analysis: 42% Potential Upside Amidst Breakthrough Biotechnology Advances - DirectorsTalk Interviews
Street Watch: What are the future prospects of Viridian Therapeutics IncJuly 2025 Catalysts & Expert Curated Trade Setup Alerts - baoquankhu1.vn
How Viridian Therapeutics Inc. (VRDN) Affects Rotational Strategy Timing - Stock Traders Daily
Analysts Offer Insights on Healthcare Companies: Veracyte (VCYT), Sarepta Therapeutics (SRPT) and Viridian Therapeutics (VRDN) - The Globe and Mail
Viridian Therapeutics' (VRDN) Buy Rating Reiterated at Needham & Company LLC - MarketBeat
VRDN: Needham Reiterates Buy Rating with Maintained Price Target | VRDN Stock News - GuruFocus
Performance Recap: Can Alerus Financial Corporation stock outperform in a bear marketMarket Trend Report & Verified Technical Signals - baoquankhu1.vn
Analysts Offer Insights on Healthcare Companies: Alphatec Holdings (ATEC), Viridian Therapeutics (VRDN) and Enovis (ENOV) - The Globe and Mail
Viridian Therapeutics (VRDN) Receives Updated Analyst Rating fro - GuruFocus
Wells Fargo & Company Forecasts Strong Price Appreciation for Viridian Therapeutics (NASDAQ:VRDN) Stock - MarketBeat
0.50%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):